A phase II study of irinotecan-cisplatin plus durvalumab for untreated extensive-stage small cell lung cancer (WJOG13520L, REBORN trial)

被引：0
|
作者：
Tachihara, M. [1 ]
Shoda, H. [2 ]
Akazawa, Y. [3 ]
Ota, T. [4 ]
Oki, M. [5 ]
Sato, Y. [6 ]
Sugawara, S. [7 ]
Ikeda, S. [8 ]
Yokoyama, T. [9 ]
Kaneda, H. [10 ]
Itoh, S. [11 ]
Bessho, A. [12 ]
Katakami, N. [13 ]
Morita, S. [14 ,15 ]
Nakagawa, K. [16 ]
Okamoto, I. [17 ]
Yamamoto, N. [18 ]
机构：
[1] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Resp Med, Kobe, Hyogo, Japan
[2] Hiroshima City Hiroshima Citizens Hosp, Dept Resp Med, Hiroshima, Japan
[3] Natl Hosp Org Toneyama Hosp, Dept Thorac Oncol, Toyonaka, Osaka, Japan
[4] Izumi Municipal Hosp Canc Ctr, Med Oncol, Izumi, Japan
[5] NHO Nagoya Med Ctr, Dept Resp Med, Nagoya, Aichi, Japan
[6] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Hyogo, Japan
[7] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan
[8] Kanagawa Cardiovasc & Resp Med, Dept Resp Med, Yokohama, Kanagawa, Japan
[9] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan
[10] Osaka Metropolitan Univ, Grad Sch Med, Clin Oncol Dept, Osaka, Japan
[11] Hyogo Canc Ctr, Resp Med Dept, Akashi, Hyogo, Japan
[12] Japanese Red Cross Okayama Hosp, Dept Resp Med, Okayama, Japan
[13] Takarazuka City Hosp, Med Oncol Dept, Takarazuka, Hyogo, Japan
[14] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[15] Kyoto Univ, Fac Med, Kyoto, Japan
[16] Kindai Univ, Sch Med, Med Oncol Dept, Main Campus, Osaka, Japan
[17] Kyushu Univ, Dept Resp Med, Fukuoka, Japan
[18] Wakayama Med Univ, Internal Med 3, Wakayama, Japan
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.672
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
639P
引用
收藏
页码：S1642 / S1642
页数：1
相关论文
共 50 条
  • [41] E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer
    Taofeek K. Owonikoko
    Joseph Aisner
    Xin Victoria Wang
    Suzanne E. Dahlberg
    Eric H. Rubin
    Suresh S. Ramalingam
    Murugesan Gounder
    Paul Gregory Rausch
    Rita S. Axelrod
    Joan H. Schiller
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 171 - 180
  • [42] Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: A Southwest Oncology Group phase II trial
    Hesketh, PJ
    Crowley, JJ
    Burris, HA
    Williamson, SK
    Balcerzak, SP
    Peereboom, D
    Goodwin, JW
    Gross, HM
    Moore, DF
    Livingston, RB
    Gandara, DR
    CANCER JOURNAL, 1999, 5 (04): : 237 - 241
  • [43] Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer
    Socinski, MA
    Neubauer, MA
    Olivares, J
    Ketchel, S
    Tynan, M
    Moore, M
    Lee, JH
    Davis, K
    Schell, M
    Garfield, D
    LUNG CANCER, 2003, 40 (01) : 91 - 97
  • [44] Phase II trial of consolidation chest radiotherapy for extensive-stage small cell lung cancer
    Yee, D.
    Butts, C. A.
    Chu, Q. S.
    Fenton, D. W.
    Joy, A.
    Reiman, T. J.
    Smylie, M.
    Roa, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Irinotecan-cisplatin therapy for patients with extensive-stage small cell lung cancer: Use patterns among American medical oncologists 2000-2006
    Green, Mark R.
    Dowlati, Afshin
    Yellamraju, Lalitha
    Daniels, Laura
    Willey, Joanne
    Andrews, Michele
    Leff, Richard
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (10) : 953 - 956
  • [46] Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
    Ni, Jun
    Si, Xiaoyan
    Wang, Hanping
    Zhang, Xiaotong
    Zhang, Li
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [47] DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive Stage Small Cell Lung Cancer
    Juloori, A.
    Gan, G.
    Zhang, J.
    Abazeed, M. E.
    Hara, J.
    Baschnagel, A. M.
    Traynor, A.
    Bassetti, M.
    Patel, J.
    Chmura, S.
    Bestvina, C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S540 - S540
  • [48] Phase II trial of irinotecan plus cisplatin (IP) and etoposide plus cisplatin (EP) given weekly on alternating weeks with granulocyte colony-stimulating factor support in the treatment of extensive-stage small cell lung cancer
    Uyeki, J.
    Johnson, F. M.
    Feng, L.
    Peeples, B. O.
    Blumenschein, G. J.
    Fossella, F. V.
    Karp, D. D.
    Pisters, K. M.
    Stewart, D. J.
    Glisson, B. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] A Phase 2 Study of Irinotecan, Cisplatin, and Simvastatin for Untreated Extensive-disease Small Cell Lung Cancer
    Han, Ji-Youn
    Lim, Kun Young
    Yu, Sun Young
    Yun, Tak
    Kim, Heung Tae
    Lee, Jin Soo
    CANCER, 2011, 117 (10) : 2178 - 2185
  • [50] A phase I and Pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer
    Lee, Dae Ho
    Kim, Sang-We
    Bae, Kyun-Seop
    Hong, Jeong-Sook
    Suh, Cheolwon
    Kang, Ybon-Koo
    Lee, Jung-Shin
    CLINICAL CANCER RESEARCH, 2007, 13 (20) : 6182 - 6186
12345